Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000982380 | SCV001130394 | likely benign | not provided | 2023-12-31 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004030067 | SCV004878125 | uncertain significance | Nephrolithiasis/nephrocalcinosis | 2023-11-21 | criteria provided, single submitter | clinical testing | The c.84-4G>A intronic alteration consists of a G to A substitution 4 nucleotides before coding exon 2 in the GRHPR gene. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001274436 | SCV001458619 | likely benign | Primary hyperoxaluria, type II | 2020-04-13 | no assertion criteria provided | clinical testing |